8-K: Oscar Health Reports Strong Q1 2026 Financials

Oscar Health announced robust first-quarter 2026 financial results, showcasing significant year-over-year improvements and reaffirming its full-year guidance.

Summary

• Oscar Health reported strong financial results for the first quarter ended March 31, 2026.
• Total revenue increased significantly to $4.65 billion from $3.05 billion in the prior year's quarter.
• The medical loss ratio (MLR) improved to 70.5% from 75.4% year-over-year.
• Selling, general, and administrative (SG&A) expense ratio decreased to 15.2% from 15.8%.
• Earnings from operations surged to $704.1 million, up from $297.1 million in Q1 2025.
• Net income attributable to Oscar Health, Inc. was $679.0 million, or $2.07 per diluted share, compared to $275.3 million, or $0.92 per diluted share, in Q1 2025.
• Adjusted EBITDA more than doubled to $727.1 million from $328.8 million.
• Membership in Individual and Small Group plans reached 3,174,489, an increase from 2,021,484 in the prior year.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a very positive report, with strong financial performance across key metrics, significant year-over-year improvements, and reaffirmed guidance, indicating robust operational health and positive future prospects.

Positives

• Significant year-over-year revenue growth of approximately 52.5%.
• Improved medical loss ratio (MLR) indicating better cost management of healthcare services.
• Reduced SG&A expense ratio, demonstrating improved operational efficiency and cost leverage.
• Substantial increase in earnings from operations, more than doubling from the previous year.
• Net income and diluted earnings per share saw a significant increase.
• Adjusted EBITDA more than doubled, indicating strong underlying operational profitability.
• Strong membership growth in the Individual and Small Group segments.
• Reaffirmation of full-year 2026 guidance, suggesting confidence in continued performance.

Negatives

• The company no longer offers small group plans as of December 15, 2024.
• The Cigna+Oscar Small Group arrangement was not renewed after December 31, 2024.
• There was an increase in the net risk adjustment transfer accrual, partially offsetting revenue growth.
• The company had $68 million of favorable prior period reserve development in Q1 2026, which contributed to the improved MLR, suggesting a portion of the improvement may not be recurring operational performance.

Risks

• Potential for unanticipated results or changes to risk adjustment programs.
• Evolving federal or state laws and regulations impacting the healthcare industry.
• Uncertainty regarding the expiration of enhanced Advanced Premium Tax Credits.
• Potential for heightened competition in the health insurance markets.
• Ability to accurately estimate incurred medical expenses and manage medical costs.
• Risks associated with data security breaches and compliance with privacy laws.
• Unfavorable outcomes of lawsuits, audits, or investigations.
• Challenges in attracting and retaining qualified personnel.

Future Outlook

Oscar Health reaffirms its full-year 2026 outlook across all metrics, indicating confidence in achieving significant margin expansion and meaningful profitability for the year. The company expects to continue its growth trajectory and focus on consumer-driven healthcare.

Management Comments

• "Oscar Health drove solid first-quarter performance with significant year-over-year improvements across our core metrics," said Mark Bertolini, CEO of Oscar Health.
• "We are reaffirming our guidance and remain on track to significantly expand margins and achieve meaningful profitability in 2026."
• "Consumers expect to shop for healthcare like everyday products on choice, price, and value. Oscar's exceptional technology, lifestyle products, and member experience deliver exactly that."
• "The workforce is shifting, the individual market is resilient, and Oscar is leading the transition to a consumer-driven health economy."

Industry Context

StockSavvy.ai notes that Oscar Health's strong Q1 2026 performance, particularly the significant revenue growth, improved MLR, and increased profitability metrics, aligns with a broader industry trend towards greater efficiency and consumer-centric healthcare models. The company's focus on technology and member experience positions it to capitalize on the shift towards a more consumer-driven health economy.

Comparison to Industry Standards

• Oscar Health's Medical Loss Ratio (MLR) of 70.5% is generally considered healthy within the health insurance industry, where regulatory minimums often hover around 80-85% for certain markets, though this metric can vary significantly by market segment and product type.
• The company's SG&A expense ratio of 15.2% appears competitive, especially for a tech-enabled health insurer, as it indicates efficient operations relative to revenue, compared to some traditional insurers who may have higher overheads.
• The substantial year-over-year growth in revenue and profitability metrics like Adjusted EBITDA suggests Oscar Health is outperforming many peers in terms of market share expansion and operational leverage, particularly within the individual and small group markets.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, and reaffirmed guidance, likely leading to increased shareholder value.
• Employees: Positive impact from company growth and success, potentially leading to job security and opportunities.
• Customers (Members): Benefit from Oscar's focus on technology, choice, price, and value in healthcare services.
• Providers: Continued engagement and partnership expected as Oscar grows and focuses on delivering quality care.
• Regulators: The company's performance and adherence to regulations will be closely monitored.

Next Steps

• Continue to execute on strategy to expand margins and achieve profitability in 2026.
• Focus on leveraging technology, lifestyle products, and member experience.
• Lead the transition to a consumer-driven health economy.
• Host conference call to discuss financial results on May 6, 2026.

Key Dates

Recommendation

The Q1 2026 results demonstrate exceptional performance with significant year-over-year improvements in revenue, profitability, and operational efficiency. The substantial increase in net income, diluted EPS, and Adjusted EBITDA, coupled with strong membership growth and reaffirmed guidance, indicates a company executing its strategy effectively and poised for continued success. The positive trends in MLR and SG&A expense ratios further support a strong outlook, making it a compelling investment opportunity.

Keywords

Oscar Health, Q1 2026 Earnings, Healthcare, Health Insurance, Financial Results, MLR, Adjusted EBITDA, Membership Growth